March 16, 2026
TOPLINE: Patients with very early axial spondyloarthritis (axSpA) who started a first TNF inhibitor within 1 year of the onset of back pain did not have […]
March 13, 2026
TOPLINE: In patients with glucocorticoid-induced osteoporosis, lumbar spine bone mineral density (BMD) increased more in those on romosozumab or teriparatide than in those on denosumab at […]
March 13, 2026
TOPLINE: Guselkumab 100 mg, administered every 4 or 8 weeks, led to significant improvements in signs and symptoms of active psoriatic arthritis (PsA) in patients with […]
March 13, 2026
A study from the UK showing that early intensive therapy was superior to standard step-up therapy for moderate-severe psoriatic arthritis (PsA) was highlighted as one of […]
March 12, 2026
The anti-CD20 therapeutic antibody obinutuzumab (Gazyva/Gazyvaro) significantly reduces multiple measures of disease activity when compared with placebo in people with active systemic lupus erythematosus (SLE) who […]
March 11, 2026
The therapeutic landscape for polymyalgia rheumatica (PMR) has grown and will grow further, allowing prolonged use of glucocorticoids (GCs) to be minimized, Anisha B. Dua, MD, […]
March 9, 2026
Deucravacitinib (Sotyktu) — an oral, selective tyrosine kinase 2 (TYK2) inhibitor — has received FDA approval for the treatment of adults with active psoriatic arthritis (PsA), […]
March 9, 2026
TOPLINE: A high proportion of patients with rheumatoid arthritis (RA) exhibited sleep impairment. Treatment with upadacitinib improved patient-reported sleep quality at 3 months, with benefits sustained […]
March 6, 2026
TOPLINE: The risk for infection in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis on immunosuppressive therapy is linked to having chronic lung disease as well as […]